AbCellera Biologics (ABCL) Accumulated Expenses (2020 - 2023)

AbCellera Biologics has reported Accumulated Expenses for 4 years, with the latest figure at $3.1 million in Q3 2023.

• For the quarter ending Q3 2023, Accumulated Expenses fell 82.64% year-over-year to $3.1 million; the trailing twelve-month figure through Sep 2023 stood at $3.1 million (down 82.64% YoY), and the FY2022 full-year result was $19.3 million, down 14.04% from the prior year.
• Accumulated Expenses for Q3 2023 stood at $3.1 million, roughly flat from $3.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $27.1 million in Q4 2020, with the low at $595000.0 in Q3 2021.
• Historically, Accumulated Expenses has averaged $14.0 million across 4 years, with a median of $18.6 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 2895.29% — and 2023, when it slumped 82.64%.
• AbCellera Biologics' Accumulated Expenses stood at $27.1 million in 2020, then fell by 17.08% to $22.5 million in 2021, then slipped by 14.04% to $19.3 million in 2022, then sank by 84.01% to $3.1 million in 2023.
• The last three Accumulated Expenses figures came in at $3.1 million (Q3 2023), $3.1 million (Q2 2023), and $3.1 million (Q1 2023), per Business Quant data.